Tamoxifen's Effect on Breast Cancer Risk in Women with BRCA1 and BRCA2 Mutations
Author Information
Author(s): Duffy S W, Nixon R M
Primary Institution: Imperial Cancer Research Fund; MRC Biostatistics Unit
Hypothesis
What is the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations?
Conclusion
Tamoxifen may provide a modest reduction in breast cancer risk for BRCA1 mutation carriers and a greater reduction for BRCA2 mutation carriers.
Supporting Evidence
- Tamoxifen has been shown to be effective in treating estrogen receptor positive tumors.
- BRCA1 mutation carriers have a modest estimated reduction in breast cancer risk of 13%.
- BRCA2 mutation carriers have a greater estimated reduction in breast cancer risk of 27%.
Takeaway
Tamoxifen can help lower the chances of getting breast cancer for women with certain gene mutations, especially more for those with BRCA2 than BRCA1.
Methodology
The study synthesized results from randomized trials and tumor surveys to estimate the preventive benefit of tamoxifen in women with BRCA mutations.
Potential Biases
The study's reliance on existing trials and tumor surveys may introduce bias due to varying methodologies and populations.
Limitations
The study assumes that the benefit of tamoxifen is primarily dependent on the estrogen receptor status of the tumors.
Participant Demographics
Women with high risk BRCA1 and BRCA2 mutations.
Statistical Information
P-Value
0.2 for BRCA1; 0.09 for BRCA2
Confidence Interval
95% CI 0.68–1.11 for BRCA1; 95% CI 0.59–0.90 for BRCA2
Statistical Significance
p=0.2 for BRCA1; p=0.09 for BRCA2
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website